Collegium Pharmaceutical (COLL) Change in Receivables (2016 - 2026)

Collegium Pharmaceutical has reported Change in Receivables for 11 years, with the latest figure at -$2.1 million in Q2 2026.

• On a quarterly basis, Change in Receivables rose 86.42% year-over-year to -$2.1 million in Q2 2026; TTM through Jun 2026 was $13.6 million, a 188.23% increase from a year earlier, with the FY2025 full-year figure at -$17.2 million, down 489.76% from the prior year.
• Change in Receivables was -$2.1 million for Q2 2026 at Collegium Pharmaceutical, down from $17.4 million in the prior quarter.
• The five-year high for Change in Receivables was $31.2 million in Q2 2022, with the low at -$22.6 million in Q4 2025.
• Average Change in Receivables over 5 years is $1.2 million, with a median of -$1.1 million recorded in 2022.
• The largest YoY upside for Change in Receivables was 10913.68% in 2025 against a maximum downside of 21240.57% in 2025.
• Over 5 years, Change in Receivables stood at -$12.3 million in 2022, then surged by 81.06% to -$2.3 million in 2023, then jumped by 95.44% to -$106000.0 in 2024, then tumbled by 21240.57% to -$22.6 million in 2025, then surged by 90.59% to -$2.1 million in 2026.
• The last three Change in Receivables figures came in at -$2.1 million (Q2 2026), $17.4 million (Q1 2026), and -$22.6 million (Q4 2025), per Business Quant data.